Stem Cell Therapeutics, University Health Network (UHN) deal

UHN granted the company an option to license exclusive, worldwide rights to tigecycline for cancer indications. The glycylcycline antibiotic is in a Phase I trial in patients with acute myelogenous leukemia (AML). The trial is expected to complete dosing in 1H13. The deadline for the option exercise is April 29, 2013. If Stem Cell exercises the option, UHN will receive an upfront payment and will be eligible for milestones and royalties. The partners declined to disclose details. ...